Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
Exegenesis Bio Inc., a gene therapy developer founded in 2019, filed for a listing on...
Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced the launch of an AI-powered R&D platform focused...
QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509) announced that its US partner Caldera Therapeutics, Inc. has...
Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific
Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the U.S. Food and Drug Administration (FDA)...
WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
WuXi Biologics (HKG: 2269) announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has...
NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
NVIDIA Corporation and Eli Lilly and Company (NYSE: LLY) announced a first‑of‑its‑kind AI co‑innovation lab to...
AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
AstraZeneca plc (AZ, NASDAQ: AZN) announced the acquisition of Modella AI, a leader in artificial intelligence...
Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
Xellsmart, a Suzhou‑based stem‑cell startup, announced the completion of RMB 400 million (USD 57.3 million) in combined Series B/B+...
WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
WuXi AppTec (SHA: 603259, HKG: 2359) released preliminary 2025 performance data, projecting full‑year revenue of...
Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
Fosun Kairos, a subsidiary of Fosun Pharma (SHA: 600196, HKG: 2196), announced a strategic cooperation...
ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced that China’s National Medical Products Administration (NMPA) has...
Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...
Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
Genhouse Bio, a small‑molecule oncology company incubated by Viva Biotech, announced the completion of a...
Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma
Haichang Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration
Iktos and Servier announced a multi‑target collaboration agreement leveraging Iktos’ AI‑orchestrated discovery platform to accelerate...
Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
Sanofi (NASDAQ: SNY) announced that the European Commission has approved Teizeild (teplizumab), a CD3‑targeted monoclonal antibody,...
CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
CSPC Pharmaceutical Group Ltd. (HKG: 1093) announced that China’s National Medical Products Administration (NMPA) has accepted...
Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk
Lifetech Scientific Corporation (HKG: 1302) announced that its Concave Supra (CS) integrated aortic arch triple‑branch reconstruction...
ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced that China’s National Medical Products Administration (NMPA) has...